Paper301897
Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas.
Gillespie GY and 3 others. J Immunol, 1977. Cited by 57 papers, by iCite.
Cite this record
ConductScience Library. Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas. Papers, record 301897. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/301897
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sarcoma, Experimental | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Cytotoxicity Tests, Immunologic | |
| Immunosuppression Therapy | |
| Male | |
| Mice | |
| Mice, Inbred BALB C | |
| Moloney murine leukemia virus | |
| Tumor Virus Infections |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 15678154 | Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. | Cancer Gene Ther | 2005 | https://conductscience.org/library/papers/15678154 | PubMed |
| 8270874 | Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. | J Exp Med | 1994 | https://conductscience.org/library/papers/8270874 | PubMed |
| 7053211 | In vitro demonstration of in situ autologous tumour-cell cytotoxicity in MSV-induced tumours in A/SN mice. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7053211 | PubMed |
| 6973602 | Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors. | J Exp Med | 1981 | https://conductscience.org/library/papers/6973602 | PubMed |
| 6201854 | Membranes from T and B lymphocytes have different patterns of tyrosine phosphorylation. | Proc Natl Acad Sci U S A | 1984 | https://conductscience.org/library/papers/6201854 | PubMed |
| 6159445 | Antigenic specificity of the cytolytic T lymphocyte response to murine sarcoma virus-induced tumors. III. Characterization of cytolytic T lymphocyte clones specific for Moloney leukemia virus-associated cell surface antigens. | J Exp Med | 1980 | https://conductscience.org/library/papers/6159445 | PubMed |
| 3876271 | Effector mechanisms of syngeneic anti-tumour responses in mice. I. Establishment and characterization of an exogenous IL-2-independent cytotoxic T-lymphocyte line specific for radiation-induced leukaemia RL male 1. | Immunology | 1985 | https://conductscience.org/library/papers/3876271 | PubMed |
| 2936448 | Immune surveillance and natural resistance: an evaluation. | Cancer Immunol Immunother | 1986 | https://conductscience.org/library/papers/2936448 | PubMed |
| 2502309 | Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host. | Cancer Immunol Immunother | 1989 | https://conductscience.org/library/papers/2502309 | PubMed |
| 2302723 | Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye. | Cancer Immunol Immunother | 1990 | https://conductscience.org/library/papers/2302723 | PubMed |
| 2289212 | Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system. | Cancer Immunol Immunother | 1990 | https://conductscience.org/library/papers/2289212 | PubMed |
| 925611 | Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors. | J Exp Med | 1977 | https://conductscience.org/library/papers/925611 | PubMed |
| 887150 | Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas. | Nature | 1977 | https://conductscience.org/library/papers/887150 | PubMed |
| 444404 | Effects of carrageenan, PVP and tumour-bearer serum on immunity induced by excision or mitomycin C-treated tumour cells in mice. | Br J Cancer | 1979 | https://conductscience.org/library/papers/444404 | PubMed |
| 375965 | Systemic and in-situ natural killer activity in tumour-bearing rats. | Br J Cancer | 1979 | https://conductscience.org/library/papers/375965 | PubMed |
| 221614 | Tumors induced by murine sarcoma virus contain precursor cells capable of generating tumor-specific cytolytic T lymphocytes. | J Exp Med | 1979 | https://conductscience.org/library/papers/221614 | PubMed |
| 81673 | Resurgence of killing and in vivo protection mediated by lymphocytes cultured from lymph nodes draining Moloney sarcomas. | Br J Cancer | 1978 | https://conductscience.org/library/papers/81673 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/301897
GET https://conductscience.org/api/papers/v1/301897/authors